| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.3 |
| Net income | -8.5 | -8.6 |
| EPS (diluted, $ a share) | $-0.71 | $-1.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SCYX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Scynexis Inc: key numbers
- Share price
- $2.91Close, Nov 16
- Market cap
- $29M
- Shares outstanding
- 9.95MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Scynexis Inc
All →Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority
SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.
- Value
- $214M
- Counterparty
- Biomedical Advanced Research and Development Authority (BARDA)
- Term
- up to 10 years
“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
Scynexis Executive Compensation
SCYNEXIS appointed Steven K. Burke, M.D., to its Board of Directors and the Nominating and Corporate Governance Committee. Dr. Burke will receive an annual cash retainer of $45,000 plus $5,000 for committee service, along with initial equity grants of 5,750 stock options and 5,750 restricted stock units. The appointment adds deep nephrology drug development expertise as the company prepares to advance its ADPKD candidate, SCY-770, into Phase 2 trials.
- Counterparty
- Steven K. Burke, M.D.